MicroRNA-224 inhibits progression of human prostate cancer by downregulating TRIB1

International Journal of Cancer

Volumn 135, Issue 3, 2014, Pages 541-550

  Lin, Zhuo Yuan ^a   Huang, Ya Qiang ^a   Zhang, Yan Qiong ^b,c   Han, Zhao Dong ^b   He, Hui Chan ^b   Ling, Xiao Hui ^a   Fu, Xin ^b   Dai, Qi Shan ^b   Cai, Chao ^a   Chen, Jia Hong ^b   Liang, Yu Xiang ^b   Jiang, Fu Neng ^b   Zhong, Wei De ^a,b   Wang, Fen ^d   Wu, Chin Lee ^e  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

^c INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^d UNIVERSITY OF TEXAS   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Biochemical recurrence free survival; Clinicopathological feature; MicroRNA 224; Prostate cancer; TRIB1

Indexed keywords

MICRORNA; MICRORNA 224; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CELL LINE; CANCER GROWTH; CANCER INHIBITION; CANCER STAGING; CANCER TISSUE; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL FEATURE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; RECURRENCE FREE SURVIVAL; TRIB1 GENE; TUMOR GENE; TUMOR INVASION; UPREGULATION; VERY ELDERLY;

BIOCHEMICAL RECURRENCE-FREE SURVIVAL; CLINICOPATHOLOGICAL FEATURE; MICRORNA-224; PROSTATE CANCER; TRIB1;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; BLOTTING, WESTERN; CELL MOVEMENT; CELL PROLIFERATION; DISEASE PROGRESSION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; PROSTATE; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84901062391     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28707     Document Type: Article

References (50)

1. Yamamoto S, Kawakami S, Yonese J, et al. Long-term oncological outcome and risk stratification in men with high-risk prostate cancer treated with radical prostatectomy. Jpn J Clin Oncol 2012; 42: 541-7.
2. Utomo NB, Mochtar CA, Umbas R,. Primary hormonal treatment in localized and locally advanced prostate cancer: effectiveness and survival predictive factors. Acta Med Indones 2012; 44: 10-15.
3. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
4. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
5. Bock CH, Schwartz AG, Ruterbusch JJ, et al. Results from a prostate cancer admixture mapping study in African-American men. Hum Genet 2009; 126: 637-42.
6. Bartel DP,. MicroRNAs: genomics, #biogenesis, |mechanism, and function. Cell 2004; 116: 281-97.
7. Calin GA, Liu CG, Sevignani C, et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci USA 2004; 101: 11755-60.
8. Porkka KP, Pfeiffer MJ, Waltering KK, et al. MicroRNA expression profiling in prostate cancer. Cancer Res 2007; 67: 6130-5.
9. He HC, Han ZD, Dai QS, et al. Global analysis of the differentially expressed miRNAs of prostate cancer in Chinese patients. BMC Genom 2013; 14: 757.
10. Mees ST, Mardin WA, Sielker S, et al. Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas. Ann Surg Oncol 2009; 16: 2339-50.
11. Liu H, Brannon AR, Reddy AR, et al. Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell renal cell carcinoma. BMC Syst Biol 2010; 4: 51.
12. Nikiforova MN, Tseng GC, Steward D, et al. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab 2008; 93: 1600-8.
13. Ladeiro Y, Couchy G, Balabaud C, et al. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology 2008; 47: 1955-63.
14. Li Q, Wang G, Shan JL, et al. MicroRNA-224 is upregulated in HepG2 cells and involved in cellular migration and invasion. J Gastroenterol Hepatol 2010; 25: 164-71.
15. Wang Y, Lee AT, Ma JZ, et al. Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target. J Biol Chem 2008; 283: 13205-15.
16. Wang YX, Zhang XY, Zhang BF, et al. Initial study of microRNA expression profiles of colonic cancer without lymph node metastasis. J Dig Dis 2010; 11: 50-4.
17. Li Z, Lu J, Sun M, et al. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci USA 2008; 105: 15535-40.
18. Prueitt RL, Yi M, Hudson RS, et al. Expression of microRNAs and protein-coding genes associated with perineural invasion in prostate cancer. Prostate 2008; 68: 1152-64.
19. White NM, Chow TF, Mejia-Guerrero S, et al. Three dysregulated miRNAs control kallikrein 10 expression and cell proliferation in ovarian cancer. Br J Cancer 2010; 102: 1244-53.
20. Iorio MV, Visone R, Di Leva G, et al. MicroRNA signatures in human ovarian cancer. Cancer Res 2007; 67: 8699-707.
21. Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006; 9: 189-98.
22. Martens-Uzunova ES, Jalava SE, Dits NF, et al. Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer. Oncogene 2012; 31: 978-91.
23. Mavridis K, Stravodimos K, Scorilas A,. Downregulation and prognostic performance of microRNA 224 expression in prostate cancer. Clin Chem 2013; 59: 261-9.
24. Giricz O, Reynolds PA, Ramnauth A, et al. HSA-MIR-375 is differentially expressed during breast lobular neoplasia and promotes loss of mammary acinar polarity. J Pathol 2012; 226: 108-19.
25. Fellenberg J, Saehr H, Lehner B, et al. A microRNA signature differentiates between giant cell tumor derived neoplastic stromal cells and mesenchymal stem cells. Cancer Lett 2012; 321: 162-8.
26. Scapoli L, Palmieri A, Lo Muzio L, et al. MicroRNA expression profiling of oral carcinoma identifies new markers of tumor progression. Int J Immunopathol Pharmacol 2010; 23: 1229-34.
27. Lewis BP, Burge CB, Bartel DP,. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are MicroRNA targets Cell 2005; 120: 15-20.
28. Maragkakis M, Alexiou P, Papadopoulos GL, et al. Accurate microRNA target prediction correlates with protein repression levels. BMC Bioinform 2009; 10: 295.
29. Krek A, Grün D, Poy MN, et al. microRNA target predictions in vertebrates. Nat Genet 2005; 37: 495-500.
30. Dweep H, Sticht C, Pandey P, et al. miRWalk-database: prediction of possible miRNA binding sites by "walking" the genes of three genomes. J Biomed Inform 2011; 44: 839-47.
31. Wang X, El Naqa IM,. Prediction of both conserved and nonconserved microRNA targets in animals. Bioinformatics 2008; 24: 325-32.
32. Betel D, Koppal A, Agius P, et al. Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. Genome Biol 2010; 11: R90.
33. Chen JH, He HC, Jiang FN, et al. Analysis of the specific pathways and networks of prostate cancer for gene expression profiles in the Chinese population. Med Oncol 2012; 29: 1972-84.
34. Sung HY, Guan H, Czibula A, et al. Human Tribbles-1 controls proliferation and chemotaxis of smooth muscle cells via MAPK signaling pathways. J Biol Chem 2007; 282: 18379-87.
35. Yokoyama T, Kanno Y, Yamazaki Y, et al. Trib1 links the pathway in myeloid leukemogenesis. Blood 2010; 116: 2768-2775.
36. Li X, Shen Y, Ichikawa H, et al. Regulation of miRNA expression by Src and contact normalization: effects on nonanchored cell growth and migration. Oncogene 2009; 28: 4272-83.
37. Hsu PP, Sabatini DM,. Cancer cell metabolism: Warburg and beyond. Cell 2008; 134: 703-7.
38. Chiaradonna F, Sacco E, Manzoni R, et al. Ras-dependent carbon metabolism and transformation in mouse fibroblasts. Oncogene 2006; 25: 5391-404.
39. Seher TC, Leptin M,. Tribbles, a cell-cycle brake that coordinates proliferation and morphogenesis during Drosophila gastrulation. Curr Biol 2000; 10: 623-9.
40. Hegedus Z, Czibula A, Kiss-Toth E,. Tribbles: a family of kinase-like proteins with potent signaling regulatory function. Cell Signal 2007; 19: 238-50.
41. Jin G, Yamazaki Y, Takuwa M,. Trib1 and Evi1 cooperate with Hoxa and Meis1 in myeloid leukemogenesis. Blood 2007; 109: 3998-4005.
42. Puskas LG, Juhasz F, Zarva A, et al. Gene profiling identifies genes specific for well-differentiated epithelial thyroid tumors. Cell Mol Biol 2005; 51: 177-86.
43. Satoh T, Kidoya H, Naito H, et al. Critical role of Trib1 in differentiation of tissue-resident M2-like macrophages. Nature 2013; 495: 524-8.
44. Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18: 11-22.
45. Zhu S, Sachdeva M, Wu F, et al. UBC9 promotes breast cell invasion and metastasis in a sumoylation-independent manner. Oncogene 2010; 29: 1763-72.
46. Lichner Z, Mejia-Guerrero S, Ignacak M, et al. Pleiotropic action of renal cell carcinoma-dysregulated miRNAs on hypoxia-related signaling pathways. Am J Pathol 2012; 180: 1675-87.
47. White NM, Bui A, Mejia-Guerrero S, et al. Dysregulation of kallikrein-related peptidases in renal cell carcinoma: potential targets of miRNAs. Biol Chem 2010; 391: 411-23.
48. Sun YX, Wang J, Shelburne CE, et al. Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem 2003; 89: 462-73.
49. de Muga S, Hernandez S, Salido M, et al. CXCR4 mRNA overexpression in high grade prostate tumors: lack of association with TMPRSS2-ERG rearrangement. Cancer Biomark 2012; 12: 21-30.
50. Kimbro KS, Simons JW,. Hypoxia-inducible factor-1 in human breast and prostate cancer. Endocr Relat Cancer 2006; 13: 739-49.